DZ Bank Call 2.374 MDGD 20.12.202.../ DE000DW83PA7 /
24/06/2024 21:34:47 | Chg.-0.009 | Bid21:55:03 | Ask- | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.001EUR | -90.00% | 0.001 Bid Size: 1,000 |
- Ask Size: - |
MEDIGENE AG NA O.N. | 2.374 EUR | 20/12/2024 | Call |
GlobeNewswire
20/06
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumor...
GlobeNewswire
28/05
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire
21/05
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
15/05
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
14/05
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GlobeNewswire
06/05
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
02/05
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell R...
GlobeNewswire
02/05
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
GlobeNewswire
25/04
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
GlobeNewswire
08/04
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR ...
GlobeNewswire
28/03
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
19/03
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire
06/03
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Pr...
GlobeNewswire
04/03
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety...